Speaker Profile
PhD, Senior Director of Computational Biology & Algorithms, Exai
Biography
As Senior Director of Computational Biology and Algorithms at Exai, Dr. Hormozdiari brings extensive research experience to his role leading the computational biology and data science team at Exai. His team is developing computational algorithms and AI models based on a novel category of cancer-associated RNAs, which can be used across multiple cancer care settings and applications, such as screening and early detection, monitoring, molecular residual disease and therapy selection. Fereydoun also holds an associate professor position at University of California, Davis where his lab is working on computational method development for understanding the etiology of complex diseases. He has been awarded the Sloan Research Award and NSF CAREER award for his work in computational biology and has been a member of large genomics consortiums such as the 1000 genomes project. Fereydoun has a Ph.D. degree and a masters degree in computing science from Simon Fraser University, Canada.
Talk
Early Cancer Detection Using Novel RNA & AI Liquid Biopsy Platform
Highly Differentiated Approach to Liquid Biopsy: Exai has identified a novel category of cancer-associated, small non-coding RNAs, termed orphan non-coding RNAs (oncRNAs). When combined with Exais proprietary artificial intelligence, this unique platform can be used across multiple cancer care settings and applications, such as screening and early detection, monitoring, molecular residual disease and therapy selection.
Clinical Dx Showcase:
Exai
Exai's mission is to enable a world where cancer can be detected early, diagnosed accurately, and treated in a personalized way. The company’s proprietary RNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest, most accurate detection of cancer.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
